The Details:
The top-line results showed no decline in cognition scores in patients with mild Alzheimer's disease who received simufilam continuously for 24 months.
“We’re fighting Alzheimer’s disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments,” said Remi Barbier, CEO of Cassava.
“Stable ADAS-Cog scores over 2 years is clearly a desirable clinical outcome in Alzheimer’s. Our data in mild patients may emphasize the importance of treating patients early in the disease.”
Cassava Sciences shares have grabbed the attention of retail investors and short-sellers alike. The stock is one of the top trending tickers on Stocktwits, and a remarkable 33.49% of available shares are being sold short.
Related News: What’s Going On With Bitcoin Miners Marathon Digital and Riot Platforms Stock?
SAVA Price Action: According to Benzinga Pro, Cassava Sciences shares are up 2.2% at $24.18 at the time of publication.
Image: Michal Jarmoluk from Pixabay
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
